Study from JAMA reveals that users of GLP-1 agonists, recent drugs for weight management, show a heightened risk of gastrointestinal complications like intestinal obstruction, gastroparesis, and pancreatitis. Though these effects are rare, those considering these drugs for weight loss should weigh the benefits against potential risks, especially if not using them for diabetes.
Cybin Completes Phase 2 Dosing Study For Major Depressive Disorder
Cybin Inc. positive news cycle keeps churning out positive developments. Today, the company announced the successful completion of dosing for the final cohort within the